Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

8,848 13,470 15,789 25,345 152,987 General and administrative 5,118 5,223 10,305 10,419 68,154 Impairment of leasehold improvements - - - - 1,030 Depreciation and amortization 332 519 653 1,024 5,311 In-process research and development - - - - 418 Total operating expenses 14,298 19,212 26,747 36,788 227,900 Loss from operations (10,491) (13,851) (19,779) (26,819) (201,181) Other income (expenses): Interest income 1,331 269 3,034 795 13,555 Interest expense (59) (41) (129) (71) (1,718) Change in fair value of warrant liability - - - - (454) Other expense - - - - (1,180) Loss before tax benefit (9,219) (13,623) (16,874) (26,095) (190,978) (Provision for)/ benefit from income taxes (75) - (150) - 695 Net loss (9,294) (13,623) (17,024) (26,095) (190,283) Deemed dividend - - - - (19,424) Preferred stock accretion - - - - (802) Net loss attributable to common stockholders $(9,294) $(13,623) $(17,024) $(26,095)$(210,509) Net loss attributable to common stockholders per common share - basic and diluted $(0.41) $(0.60) $(0.76) $(1.15) Weighted-average common shares outstanding - basic and diluted 22,467,198 22,618,026 22,439,893 22,615,951


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
(Date:7/24/2014)... -- Neogen Corporation (Nasdaq: NEOG ) advised market ... from new rodenticide research are premature. In its regular ... 22, 2014, Neogen,s CEO commented about several new developments ... "It was my intent Tuesday at our conference call ... type of rodenticide, but certainly not to give any ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... SAN DIEGO, May 9, 2011 Ardea Biosciences, Inc. ... on the development of small-molecule therapeutics for the treatment ... results for the first quarter ended March 31, 2011. ... lesinurad in combination with allopurinol demonstrate lesinurad,s potential to ...
... 9, 2011 Cell Biosciences, Inc. today announced the ... Patent and Trademark Office, Patent Nos. 7,935,489, 7,935,308 and ... Cell Biosciences, NanoPro™ Assay Technology. NanoPro assay systems utilize ... high-sensitivity measurement of specific proteins in complex biological samples. ...
... May 9, 2011 BD Diagnostics, a segment of ... (NYSE: BDX ), and Diagenode SA, an ... agreement to co-develop seven initial molecular diagnostic assays on ... enteric and central nervous system diseases.   ...
Cached Biology Technology:Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 6BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System 2BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System 3BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System 4
(Date:7/24/2014)... has its own microbial terroir, meaning the microbial populations ... in the product, creating the final flavor according to ... Applied and Environmental Microbiology . This is the first ... sake brewery. , Many sake makers inoculate with ... Mills of the University of California, Davis, but he ...
(Date:7/24/2014)... Albert Einstein College of Medicine of Yeshiva ... Fox Foundation for Parkinson,s Research to translate a basic ... drug discovery project will test chemical compounds on a ... drug that acts on an underlying cause of the ... many people manage their symptoms, we are eager to ...
(Date:7/24/2014)... molecules, which have similar counterparts in humans, affect the ... nerve signals into the hippocampus, an area of the ... and the creation of memories. The results of the ... . , Brain function depends on the active communication ... neurons are woven together into a dense network where ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4
... of their brain that helps them appreciate the pain their ... of the brain connected with controlling emotions, according to new ... Because doctors sometimes have to inflict pain on their ... develop the ability to not be distracted by the suffering, ...
... acquired 12,000 new animalsmicroscopic Elkhorn coral larvae harvested ... of an international collaborative program to raise the ... day return the animals, once they are grown, ... Zoo Reproductive Scientist Dr. Mary Hagedorn and Invertebrates ...
... alAbsi, Ph.D., and a team of national collaborators have ... National Institutes of Health (NIH) for their research, AutoSense: ... alAbsi is a professor and founding director of Duluth ... SchoolDuluth Campus. , The project is among the first ...
Cached Biology News:Doctors learn to control their own brains' pain responses to better treat patients 2Doctors learn to control their own brains' pain responses to better treat patients 3Smithsonian scientists working to save microscopic threatened species 2Mustafa al'Absi Ph.D. and national team awarded major NIH grant 2
...
... cytostatic and anti-viral agent. Inhibits several important steps ... formation of HUVEC cells. Also reduces intracellular reactive ... IL-8 release of endothelial cells. ... 16 O 8 MolWeight: ...
... includes the pZErO-1 vector with Zeocin resistance ... vector utilizes positive selection to eliminate high ... resistance gene reduces the overall vector size ... kit contains all of the reagents you ...
NATIVE, ENZYME PORCINE TRYPSIN...
Biology Products: